According to TipRanks.com, Phipps is ranked 0 out of 5 stars with an average return of -7.4% and a 41.3% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics, Chinook Therapeutics, and Tempest Therapeutics.
Currently, the analyst consensus on Dynavax is a Strong Buy with an average price target of $24.00.
The company has a one-year high of $21.39 and a one-year low of $7.26. Currently, Dynavax has an average volume of 2.44M.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DVAX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
Read More on DVAX: